Lobbying client
DR. EMIL KAKKIS
CEO of biotechnology company focusing on rare diseases.
Filings
4
Filed by
1
Reported in-house
—
Reported by firms
$100,000
Reported lobbying by year
The larger of in-house and firm-reported each year, $ thousands
2023 to 2024
Filings
4 filings, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
2nd Quarter - Termination (No Activity) 2nd Quarter 2024
|
WILLIAMS AND JENSEN, PLLC | — reported |
|
1st Quarter - Report 1st Quarter 2024
|
WILLIAMS AND JENSEN, PLLC | $50,000 reported |
|
4th Quarter - Report 4th Quarter 2023
|
WILLIAMS AND JENSEN, PLLC | $50,000 reported |
|
Registration 4th Quarter 2023
|
WILLIAMS AND JENSEN, PLLC | — reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| WILLIAMS AND JENSEN, PLLC | 3 | $100,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Health Issues | HCR | 3 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.